The
pace and performance of modern drug discovery and development
is based on effective use of a range of technologies. From
initial screening to lead identification and drug delivery,
emerging technologies are accelerating the drug development.
These technologies are also contributing immensely to improvements
in the quality and productivity of drug manufacturing. Nanotechnology
and ICT are among the most exciting additions in the technology
paradigm which hold great promises for future. It is expected
that these technologies will not only decrease the cost of
the drug development but also reduce the time required for
a lead molecule to emerge as a drug for clinical use.
This exciting track will showcase the R&D in emerging
technologies to facilitate the drug discovery development
process. Based on the very nature of the topic, the speakers
and other presenters will include biomedical engineers, physicists,
ICT experts, as well as medicinal chemists and health professionals.
This important track will be of great interest for scientists,
specially with reference to introducing new cutting edge technologies
many of which are still not known widely.
The 2nd ICDDT to be held in Dubai in February 2010 will address
all areas pertinent to this endeavor concentrating on leads
that arise from application of the new knowledge at the cellular
and molecular level. The other areas will highlight the impact
of Nanomedicine (Application of nanotechnology in Human Health)
on diagnosis and treatment of diseases. Nanomedicine is an
emerging and expanding field with innumerable applications
and may play an important role is translational research or
moving from laboratory research to clinical practice.
Sanjeeb K. Sahoo
Institute of Life Sciences
Bhubaneswar, India
|
| 
| | Dr
Sahoo is a scientist at the Institute of Life Sciences, Bhubaneswar,
India. Dr. Sahoo received his M.Sc. degree in 1994 and Ph.D
in 1999 from the University of Delhi, Delhi. He served as
a JSPS Postdoctoral fellow at the Department of Microbiology,
School of Medicine, Kumamoto University, Kumamoto, Japan from
1999-2001 followed by a four year postdoctoral fellowship
at the Nebraska Medical Centre, Omaha, USA from 2001-2005.
During his postdoctoral studies, he acquired good knowledge
and experience in the art of making different nanotechnology
based drug delivery systems for therapeutic use. Dr. Sahoo
is one of the first inventors of India whose nanotechnology
based patented formulation on anticancer drug (taxol) delivery
has been purchased by an Indian Pharmaceutical industry and
very soon it will be in the market. |
| Scientific Contributions
includes over more than 40 peer reviewed research
papers including review articles and book chapters. Dr. Sahoo
has been granted 5 US patents, 1 EU patent and 3 Indian patents
on Nanotechnology based targeted drug and gene delivery. Two
of his technologies have already been transformed to different
pharmaceutical companies. He is one of the experts in the
field of Nanotechnology based drug delivery system mainly
in the field of Cancer. Three of his papers [The FASEB Journal,
Vol. 16, 1217-1226, 2002: J. Control. Release. Vol. 82, 105-114,
2002 and Drug Discovery Today. 8 (24), 1112-1120, 2003] has
been cited 208, 145 and 132 times respectively, till date.
In addition, the total citations to date are more than 1150
times. A couple of his papers have been listed on the National
Cancer Institute (NCI), USA web site under NCI Alliance for
Nanotechnology in Cancer. Dr. Sahoo's work is of high quality
and highly relevant to clinical applications of drug delivery
based Pharmaceutical Industry.
Scientific and Professional Activities include Editorial board membership of International Journal of Green Nanotechnology, Taylor & Francis, USA. He is the member of different scientific organizations like the Controlled Release Society and The American Association for Pharmaceutical Sciences.
|
|
